Stocktoria
Incannex Healthcare Inc. IXHL
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2022-03-18
Incannex Healthcare Inc. financials (annual)
Bars are annual figures from 2023 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2023 |
|---|---|---|---|---|
| Revenue | $86,000 | $12,000 | — | — |
| R&D expense | $10.7M | $12.9M | — | $6.3M |
| Operating income | -$23.8M | -$30.0M | — | -$49.7M |
| Income tax | — | $30,000 | — | — |
| Net income | -$46.9M | -$18.5M | — | -$48.8M |
| EPS (diluted) | $-1.35 | $-1.15 | — | $-3.32 |
| Operating cash flow | -$12.5M | -$15.8M | — | -$10.7M |
| Free cash flow | -$12.5M | -$16.1M | — | -$11.1M |
| Cash & equivalents | $15.0M | $5.9M | $14.6M | $22.1M |
| Total assets | $20.4M | $17.0M | $22.4M | $23.8M |
| Total liabilities | $7.1M | $5.8M | $3.5M | $3.0M |
| Shareholders' equity | $13.4M | $11.2M | $18.9M | $20.8M |
Growth · year-over-year · Revenue CAGR 616.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2023 |
|---|---|---|---|---|
| Revenue growth | +616.7% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.